Lyell Immunopharma (LYEL) EBITDA Margin Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,609.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1,536.00 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -957.00 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 8,807.00 |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -47.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.27 Mn |
| Dec 31, 2025 | -59.56 Mn |
| Sep 30, 2025 | -13.03 Mn |
| Jun 30, 2025 | -18.25 Mn |
| Mar 31, 2025 | 128.50 Mn |
| Dec 31, 2024 | -135.03 Mn |
| Sep 30, 2024 | 7.09 Mn |
| Jun 30, 2024 | -12.12 Mn |
| Mar 31, 2024 | -193.53 Mn |
| Dec 31, 2023 | -39.88 Mn |
| Sep 30, 2023 | 219.80 Mn |
| Jun 30, 2023 | -23.10 Mn |
| Mar 31, 2023 | -8.41 Mn |
| Dec 31, 2022 | 300,900.00 |
| Sep 30, 2022 | -239.49 Mn |
| Jun 30, 2022 | 227,875.00 |
| Mar 31, 2022 | -1.10 Mn |
| Dec 31, 2021 | -132,616.00 |
| Sep 30, 2021 | 161,506.00 |
| Jun 30, 2021 | 83,958.00 |